Pfizer, BioNTech say data shows the booster dose led to a substantial increase in neutralizing antibody levels against the BA.4/BA.5 variants after one week
Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants of Omicron, generated a strong immune response and was well-tolerated in testing on humans.
Healthcare regulators for the European Union and the United States had already approved the upgraded shot last month, even though trial data from testing on humans had at the time not been available. “While we expect more mature immune response data from the clinical trial of our Omicron BA.4/BA.5-adapted bivalent vaccine in the coming weeks, we are pleased to see encouraging responses just one week after vaccination in younger and older adults,” said Pfizer Chief Executive Albert Bourla.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Residents continue to get the Moderna bivalent shot, but some waiting for PfizerThe Moderna bivalent booster has been available to adults since Sept. 26, but it seems like the rush to get vaccinated might be over. Some might just be waiting for Pfizer’s new shot.
Read more »
FDA clears updated COVID boosters for kids as young as 5The U.S. on Wednesday authorized updated COVID-19 boosters for children as young as five, seeking to expand protection ahead of an expected winter wave.
Read more »